Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

Area of Science:

• Immunology
• Metabolomics
• COVID-19 Research

Background:

• COVID-19 presents a wide spectrum of disease severity.
• Understanding the early systemic changes in COVID-19 is crucial for effective treatment.

Purpose of the Study:

• To investigate the integrated clinical, immune, and metabolic profiles of COVID-19 patients across disease severities.
• To identify key transition points and biological drivers of disease progression.

Main Methods:

• Integrated analysis of clinical data, immune cell phenotypes, and plasma multi-omics from 139 COVID-19 patients.
• Serial blood draws during the first week post-diagnosis.
• Dimensionality reduction of over 120,000 immune features into a single response axis.

Main Results:

• A significant shift in plasma metabolites and metabolic processes occurs between mild and moderate COVID-19.
• Emergence and amplification of unusual immune cell phenotypes in moderate to severe disease.
• An "immune-response axis" correlates with plasma changes, blood clotting, and disease severity transition.

Conclusions:

• Moderate COVID-19 represents a critical juncture with distinct metabolic and immune alterations.
• The identified immune-response axis provides a unified view of host response to SARS-CoV-2.
• Therapeutic interventions during the moderate disease stage may be most effective.